Ironwood Pharmaceuticals (IRWD) Revenue & Revenue Breakdown
Ironwood Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$442.74M
Latest Revenue (Q)
$94.40M
Main Segment (Y)
Collaborative arrangements revenue
Main Geography (Y)
North America
Ironwood Pharmaceuticals Revenue by Period
Ironwood Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $442.74M | 7.83% |
| 2022-12-31 | $410.60M | -0.76% |
| 2021-12-31 | $413.75M | 6.22% |
| 2020-12-31 | $389.52M | -9.08% |
| 2019-12-31 | $428.41M | 23.59% |
| 2018-12-31 | $346.64M | 16.21% |
| 2017-12-31 | $298.28M | 8.88% |
| 2016-12-31 | $273.96M | 83.18% |
| 2015-12-31 | $149.56M | 95.66% |
| 2014-12-31 | $76.44M | 234.06% |
| 2013-12-31 | $22.88M | -84.77% |
| 2012-12-31 | $150.25M | 128.09% |
| 2011-12-31 | $65.87M | 50.19% |
| 2010-12-31 | $43.86M | 21.48% |
| 2009-12-31 | $36.10M | 62.50% |
| 2008-12-31 | $22.22M | 112.31% |
| 2007-12-31 | $10.46M | - |
Ironwood Pharmaceuticals generated $442.74M in revenue during NA 2023, up 7.83% compared to the previous quarter, and up 127.72% compared to the same period a year ago.
Ironwood Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $94.40M | 26.07% |
| 2024-03-31 | $74.88M | -36.30% |
| 2023-12-31 | $117.55M | 3.35% |
| 2023-09-30 | $113.74M | 5.92% |
| 2023-06-30 | $107.38M | 3.19% |
| 2023-03-31 | $104.06M | -2.93% |
| 2022-12-31 | $107.20M | -1.32% |
| 2022-09-30 | $108.64M | 11.73% |
| 2022-06-30 | $97.23M | -0.31% |
| 2022-03-31 | $97.53M | -16.73% |
| 2021-12-31 | $117.13M | 12.90% |
| 2021-09-30 | $103.75M | -0.27% |
| 2021-06-30 | $104.03M | 17.09% |
| 2021-03-31 | $88.84M | -23.86% |
| 2020-12-31 | $116.68M | 12.77% |
| 2020-09-30 | $103.47M | 15.69% |
| 2020-06-30 | $89.43M | 11.87% |
| 2020-03-31 | $79.94M | -36.70% |
| 2019-12-31 | $126.30M | -3.71% |
| 2019-09-30 | $131.17M | 28.32% |
| 2019-06-30 | $102.22M | 48.72% |
| 2019-03-31 | $68.73M | -47.41% |
| 2018-12-31 | $130.69M | 98.96% |
| 2018-09-30 | $65.69M | -19.01% |
| 2018-06-30 | $81.11M | 17.28% |
| 2018-03-31 | $69.16M | -26.59% |
| 2017-12-31 | $94.21M | 8.50% |
| 2017-09-30 | $86.83M | 33.42% |
| 2017-06-30 | $65.08M | 24.75% |
| 2017-03-31 | $52.17M | -40.35% |
| 2016-12-31 | $87.46M | 32.30% |
| 2016-09-30 | $66.11M | 21.63% |
| 2016-06-30 | $54.35M | -17.70% |
| 2016-03-31 | $66.04M | 23.89% |
| 2015-12-31 | $53.31M | 34.71% |
| 2015-09-30 | $39.57M | 42.63% |
| 2015-06-30 | $27.74M | -4.11% |
| 2015-03-31 | $28.93M | -24.01% |
| 2014-12-31 | $38.07M | 125.04% |
| 2014-09-30 | $16.92M | 147.34% |
| 2014-06-30 | $6.84M | -53.17% |
| 2014-03-31 | $14.61M | 190.30% |
| 2013-12-31 | $5.03M | 2.01% |
| 2013-09-30 | $4.93M | -48.96% |
| 2013-06-30 | $9.66M | 196.87% |
| 2013-03-31 | $3.25M | -87.94% |
| 2012-12-31 | $26.98M | -72.02% |
| 2012-09-30 | $96.41M | 560.18% |
| 2012-06-30 | $14.60M | 19.24% |
| 2012-03-31 | $12.25M | -61.91% |
| 2011-12-31 | $32.15M | 163.17% |
| 2011-09-30 | $12.22M | 8.49% |
| 2011-06-30 | $11.26M | 10.01% |
| 2011-03-31 | $10.24M | -38.96% |
| 2010-12-31 | $16.77M | 85.14% |
| 2010-09-30 | $9.06M | -17.34% |
| 2010-06-30 | $10.96M | 21.07% |
| 2010-03-31 | $9.05M | 5.21% |
| 2009-12-31 | $8.60M | -43.61% |
| 2009-09-30 | $15.26M | 130.82% |
| 2009-06-30 | $6.61M | 26.36% |
| 2009-03-31 | $5.23M | 5.17% |
| 2008-12-31 | $4.97M | - |
Ironwood Pharmaceuticals generated $94.40M in revenue during Q2 2024, up 26.07% compared to the previous quarter, and up 90.71% compared to the same period a year ago.
Ironwood Pharmaceuticals Revenue Breakdown
Ironwood Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Collaborative arrangement, co-promotion agreements | $2.01M | $2.19M | $2.41M | - | - |
| Collaborative arrangement, collaboration and license agreements | $1.80M | $635.00K | $743.00K | - | - |
| Royalty | $2.20M | $100.00K | - | - | - |
| Collaborative arrangement, other agreements | $2.48M | $1.82M | $1.75M | - | - |
| Collaborative arrangements revenue | $442.74M | $410.60M | $412.78M | - | - |
| Sale of active pharmaceutical ingredient | - | - | $969.00K | - | - |
| Collaborative Arrangement Collaboration And License Agreements Upfront Fee | - | - | - | $10.00M | - |
| Collaborative Arrangement Collaboration And License Agreements | - | - | - | $700.00K | - |
| Collaborative Arrangement Transition Services Agreement | - | - | - | $600.00K | - |
| Collaborative Arrangement Collaboration Agreements | - | - | - | $32.40M | - |
| Collaborative Arrangement Co Promotion Agreement | - | - | - | $4.30M | $2.00M |
| Collaborative Arrangement Promotion Agreement | - | - | - | $3.50M | $3.70M |
| Collaborative Arrangements | - | - | - | - | $379.65M |
| Active Pharmaceutical Ingredient | - | - | - | - | $48.76M |
| Collaborative Arrangement Other Agreements | - | - | - | - | $1.84M |
Ironwood Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaborative arrangements revenue (98.12%), Collaborative arrangement, other agreements (0.55%), Royalty (0.49%), Collaborative arrangement, co-promotion agreements (0.45%), and Collaborative arrangement, collaboration and license agreements (0.40%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative arrangement, other agreements | $516.00K | $580.00K | $570.00K | $365.00K | $409.00K | $480.00K | $396.00K | $547.00K | $408.00K | - | - | - | - | - | - | - | - | - | - | - |
| Collaborative arrangement, collaboration and license agreements | $368.00K | $121.00K | $91.00K | $151.00K | $144.00K | $148.00K | $192.00K | $114.00K | $219.00K | $200.00K | - | - | - | - | - | - | - | - | - | - |
| Collaborative arrangements revenue | - | $107.38M | $104.06M | $107.20M | $108.64M | $97.23M | $97.53M | $116.99M | $103.75M | $103.39M | - | - | - | - | - | - | - | - | - | - |
| Collaborative arrangement, co-promotion agreements | - | - | - | - | $814.00K | $585.00K | $823.00K | $676.00K | $683.00K | $596.00K | - | - | - | - | - | - | - | - | - | - |
| Sale of active pharmaceutical ingredient | - | - | - | - | - | - | - | $144.00K | $645.00K | - | - | - | - | - | - | - | - | - | - | - |
| Collaborative Arrangement Transition Services Agreement | - | - | - | - | - | - | - | - | - | - | $100.00K | - | - | - | - | - | - | - | - | - |
| Active Pharmaceutical Ingredient | - | - | - | - | - | - | - | - | - | - | $180.00K | $20.65M | $643.00K | $24.89M | $2.58M | $45.86M | - | - | - | - |
| Royalty | - | - | - | - | - | - | - | - | - | - | $100.00K | $300.00K | $200.00K | $200.00K | - | - | - | - | - | - |
| Collaborative Arrangement Collaboration And License Agreements | - | - | - | - | - | - | - | - | - | - | $200.00K | - | - | - | - | - | - | - | - | - |
| Collaborative Arrangements | - | - | - | - | - | - | - | - | - | - | $88.67M | $105.65M | $130.52M | $77.32M | - | - | - | - | - | - |
| Collaborative Arrangement Promotion Agreement | - | - | - | - | - | - | - | - | - | - | - | $400.00K | $1.10M | $1.10M | $900.00K | $2.30M | - | - | - | - |
| Collaborative Arrangement Co Promotion Agreement | - | - | - | - | - | - | - | - | - | - | - | $1.20M | $1.10M | $1.06M | $1.28M | $2.60M | $1.24M | - | - | - |
| License And Service | - | - | - | - | - | - | - | - | - | - | - | - | $900.00K | $900.00K | $900.00K | - | - | - | - | - |
| Collaborative Arrangement Co Promotion And Other Agreements | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $945.00K | $500.00K | - | - | - | - |
| Collaborative Arrangement Other Agreements | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $229.00K | $346.00K | $323.00K | - | - |
| Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $479.00K |
Ironwood Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaborative arrangement, other agreements (58.37%), and Collaborative arrangement, collaboration and license agreements (41.63%).
Ironwood Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| North America | $433.24M | $2.73M | $2.71M | $2.30M | $2.16M |
| Europe and Other | $2.80M | $2.40M | $2.60M | - | - |
| Canada and Mexico | - | $2.70M | $2.70M | - | - |
| Europe And Other | - | - | - | $2.20M | $1.72M |
| U | - | - | - | $368.60M | $325.43M |
| Europe | - | - | - | $2.20M | $1.70M |
| Canada And Mexico | - | - | - | $2.30M | $2.20M |
| J | - | - | - | - | $27.50M |
| China Hong Kong And Macau | - | - | - | - | $200.00K |
Ironwood Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: North America (99.36%), and Europe and Other (0.64%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $72.45M | $431.81M | $731.00K | $700.00K | $679.00K | $861.00K | $609.00K | $582.00K | $765.00K | $668.00K | $731.00K | $550.00K | $605.00K | $721.00K | $423.00K | $550.00K | $603.00K | - | - | - |
| Europe and Other | $706.00K | $597.00K | $702.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Canada and Mexico | - | - | $700.00K | $700.00K | $600.00K | $900.00K | $600.00K | $600.00K | $800.00K | $700.00K | $700.00K | - | - | - | - | - | - | - | - | - |
| Canada And Mexico | - | - | - | - | - | - | - | - | - | - | - | $600.00K | $600.00K | $700.00K | $400.00K | $600.00K | $600.00K | - | - | - |
| Europe And Other | - | - | - | - | - | - | - | - | - | - | - | - | $603.00K | $510.00K | $440.00K | $643.00K | $510.00K | $526.00K | $262.00K | - |
| Europe | - | - | - | - | - | - | - | - | - | - | - | - | $600.00K | $500.00K | $400.00K | $600.00K | $500.00K | - | - | - |
| China Hong Kong And Macau | - | - | - | - | - | - | - | - | - | - | - | - | - | $100.00K | $200.00K | $200.00K | $227.00K | $32.40M | - | - |
| J | - | - | - | - | - | - | - | - | - | - | - | - | - | $500.00K | $500.00K | $400.00K | $88.00K | $10.06M | $24.89M | $2.58M |
| U | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $71.14M | $101.60M | - | - | - |
Ironwood Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 24: North America (99.04%), and Europe and Other (0.96%).
Ironwood Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| ASRT | Assertio | $152.07M | $31.13M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
IRWD Revenue FAQ
What is Ironwood Pharmaceuticals’s yearly revenue?
Ironwood Pharmaceuticals's yearly revenue for 2023 was $442.74M, representing an increase of 7.83% compared to 2022. The company's yearly revenue for 2022 was $410.6M, representing a decrease of -0.76% compared to 2021. IRWD's yearly revenue for 2021 was $413.75M, representing an increase of 6.22% compared to 2020.
What is Ironwood Pharmaceuticals’s quarterly revenue?
Ironwood Pharmaceuticals's quarterly revenue for Q2 2024 was $94.4M, a 26.07% increase from the previous quarter (Q1 2024), and a -12.09% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $74.88M, a -36.30% decrease from the previous quarter (Q4 2023), and a -28.05% decrease year-over-year (Q1 2023). IRWD's quarterly revenue for Q4 2023 was $117.55M, a 3.35% increase from the previous quarter (Q3 2023), and a 9.66% increase year-over-year (Q4 2022).
What is Ironwood Pharmaceuticals’s revenue growth rate?
Ironwood Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 7.00%, and for the last 5 years (2019-2023) was 3.34%.
What are Ironwood Pharmaceuticals’s revenue streams?
Ironwood Pharmaceuticals's revenue streams in c 23 are Collaborative arrangement, co-promotion agreements, Collaborative arrangement, collaboration and license agreements, Royalty, Collaborative arrangement, other agreements, and Collaborative arrangements revenue. Collaborative arrangement, co-promotion agreements generated $2.01M in revenue, accounting 0.45% of the company's total revenue, down -8.43% year-over-year. Collaborative arrangement, collaboration and license agreements generated $1.8M in revenue, accounting 0.40% of the company's total revenue, up 183.31% year-over-year. Royalty generated $2.2M in revenue, accounting 0.49% of the company's total revenue, up 2100.00% year-over-year. Collaborative arrangement, other agreements generated $2.48M in revenue, accounting 0.55% of the company's total revenue, up 35.75% year-over-year. Collaborative arrangements revenue generated $442.74M in revenue, accounting 98.12% of the company's total revenue, up 7.83% year-over-year.
What is Ironwood Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Ironwood Pharmaceuticals was Collaborative arrangements revenue. This segment made a revenue of $442.74M, representing 98.12% of the company's total revenue.